Organon (OGN) EBIT (2020 - 2026)

Organon has reported EBIT for 7 years, with the latest figure at $323.0 million in Q2 2026.

• On a quarterly basis, EBIT changed 0.31% year-over-year to $323.0 million in Q2 2026; TTM through Jun 2026 was $1.1 billion, a 9.27% decrease from a year earlier, with the FY2025 full-year figure at $1.1 billion, down 22.27% from the prior year.
• EBIT was $323.0 million for Q2 2026 at Organon, up from $235.0 million in the prior quarter.
• The five-year high for EBIT was $539.0 million in Q1 2022, with the low at $210.0 million in Q4 2025.
• Average EBIT over 5 years is $337.4 million, with a median of $341.0 million recorded in 2025.
• The sharpest annual moves came in 2023 and 2024: EBIT slumped 43.14% in 2023, then soared 68.1% in 2024.
• Over 5 years, EBIT stood at $262.0 million in 2022, then retreated by 7.63% to $242.0 million in 2023, then rose by 19.01% to $288.0 million in 2024, then slipped by 27.08% to $210.0 million in 2025, then jumped by 53.81% to $323.0 million in 2026.
• The last three EBIT figures came in at $323.0 million (Q2 2026), $235.0 million (Q1 2026), and $210.0 million (Q4 2025), per Business Quant data.